Benjamin B. Suttle
Impact in
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
-
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Cancer-related gene regulation
- Protein Degradation and Inhibitors
- Chromatin Remodeling and Cancer
- RNA modifications and cancer
Papers in
- Oncology 2
- Colorectal Cancer Treatments and Studies 1
-
- Pharmacogenetics and Drug Metabolism 1
- Co-authors
- Vincent Ribrag (2 shared papers)Jean‐Marie Michot (2 shared papers)Peter T. C. Ho (1 shared paper)Antoîne Italiano (1 shared paper)Maud Toulmonde (1 shared paper)Andrea Varga (1 shared paper)Mark P. Woodruff (1 shared paper)Jean‐Michel Coindre (1 shared paper)
- Journals
- Cancer Chemotherapy and Pharmacology (1 paper)Pharmaceutical Research (1 paper)European Journal of Cancer (1 paper)Molecular Cancer Therapeutics (1 paper)Clinical Pharmacology & Therapeutics (1 paper)
- Partner nations
- United StatesFranceNetherlands
In The Last Decade
Benjamin B. Suttle
7 papers receiving 589 citations
Benjamin B. Suttle's Hit Papers
Peers
Comparison fields: 5 of 50
- Pathology and Forensic Medicine 139
- Molecular Biology 398
- Oncology 142
- Cancer Research 63
- Genetics 41
Countries citing papers authored by Benjamin B. Suttle
This map shows the geographic impact of Benjamin B. Suttle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin B. Suttle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin B. Suttle more than expected).
Fields of papers citing papers by Benjamin B. Suttle
This network shows the impact of papers produced by Benjamin B. Suttle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin B. Suttle. The network helps show where Benjamin B. Suttle may publish in the future.
Co-authors
The 25 scholars most cited alongside Benjamin B. Suttle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study Hit paper breakdown → | 2018 | 512 |
| 2 | 2020 | 61 | |
| 3 | 1995 | 14 | |
| 4 | 2011 | 3 | |
| 5 | A STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D) | 2014 | 3 |
| 6 | 2003 | 2 | |
| 7 | 2024 | 1 |
About Benjamin B. Suttle
Benjamin B. Suttle is a scholar working on Oncology, Pharmacology, Analytical Chemistry, Cancer Research and Molecular Biology, having authored 7 papers that have together received 596 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (1 paper), Protease and Inhibitor Mechanisms (1 paper), Analytical Methods in Pharmaceuticals (1 paper), Pharmacogenetics and Drug Metabolism (1 paper), PI3K/AKT/mTOR signaling in cancer (1 paper), Chromatin Remodeling and Cancer (1 paper), Renal cell carcinoma treatment (1 paper) and Pharmaceutical studies and practices (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (139 citations), Molecular Biology (398 citations), Oncology (142 citations), Cancer Research (63 citations) and Genetics (41 citations). Benjamin B. Suttle has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include Vincent Ribrag, Jean‐Marie Michot, Peter T. C. Ho, Antoîne Italiano, Maud Toulmonde, Andrea Varga, Mark P. Woodruff, Jean‐Michel Coindre, Carlo Lucchesi and Scott A. Ribich. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Pharmaceutical Research, European Journal of Cancer, Molecular Cancer Therapeutics and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.